{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:05:16Z","timestamp":1791864316489,"version":"4.3.4"},"reference-count":27,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"unspecified","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Shanghai Xinxin Medical Technology Development Foundation","award":["KY-HXZ-20240511-001"],"award-info":[{"award-number":["KY-HXZ-20240511-001"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Haemodialysis (HD) is an essential treatment for end-stage renal disease patients to improve their quality of life. However, conventional HD may not effectively remove medium and large molecules and protein-bound toxins, leading to the occurrence of various complications. Haemoadsorption (HA), on the other hand, can address this limitation. Therefore, a multicentre, open-label, randomised, parallel controlled study will be conducted to compare HA combined with HD (HAHD) with HD alone in maintenance haemodialysis (MHD) patients. The primary endpoint is the change in serum \u03b22-MG, PTH and CRP values.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>We plan to enrol 410 MHD patients from 10 participating medical centres in Shanghai. Patients will experience a 4-week washout period and a 52-week observation period. After the washout period, the eligible patients will be randomised in a 1:1 ratio to the two groups: the control group, 3 times\/week conventional HD treatment; and the experiment group, 3 times\/week conventional HD treatment+1 time\/week HA treatment. The baseline and follow-up data at 0, 4, 12, 24, 36 and 52 weeks were collected from both groups, including the following: medical history, routine physical examination, dialysis regimen, laboratory tests, dialysis adequacy as defined by standard Kt\/V, chest X-ray, ECG, cardiac ultrasound and three scales. Comorbidities, combined medications and adverse events will also be captured. The primary outcomes will include change in serum \u03b22-MG, PTH and CRP values. Secondary outcomes will include change values for serum protein-bound toxins, improvement in patient quality of life, sleep disturbance and pruritus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol has been approved by the Ethics Committees of 10 participating medical centres. Shanghai Changhai Hospital Ethics Committee will oversee the study. The results will be presented at national and international academic meetings, and publications will be submitted to peer-reviewed journals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05639010\">NCT05639010<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-107017","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:25:51Z","timestamp":1762946751000},"page":"e107017","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of combined haemodialysis-haemoadsorption therapy in maintenance haemodialysis patients: study protocol for a multicentre, open-label, randomised, parallel controlled trial"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05639010","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6298-1018","authenticated-orcid":false,"given":"Weiyan","family":"Huang","sequence":"first","affiliation":[{"name":"Department of Nephrology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China"},{"name":"Department of Nephrology, 903rd Hospital of PLA, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"2025120413271332000_15.11.e107017.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30045-3"},{"key":"2025120413271332000_15.11.e107017.2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00924.x"},{"key":"2025120413271332000_15.11.e107017.3","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-012-0258-1"},{"key":"2025120413271332000_15.11.e107017.4","doi-asserted-by":"publisher","DOI":"10.1053\/j.jrn.2011.10.026"},{"key":"2025120413271332000_15.11.e107017.5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000170011","article-title":"Combined hemodialysis-hemoperfusion in the treatment of secondary hyperparathyroidism of uremic patients","volume":"9","author":"Morachiello","year":"1991","journal-title":"Blood Purif"},{"key":"2025120413271332000_15.11.e107017.6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000365447","article-title":"Serum \u03b22-microglobulin correlates positively with left ventricular hypertrophy in long-term hemodialysis patients","volume":"128","author":"Masuda","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"2025120413271332000_15.11.e107017.7","first-page":"507","article-title":"\u03922 microglobulin amyloidosis: an update 30 years later","volume":"31","author":"Jadoul","year":"2016","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"2025120413271332000_15.11.e107017.8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5527\/wjn.v4.i1.98","article-title":"Role of \u03b22-microglobulin in uremic patients may be greater than originally suspected","volume":"4","author":"Zumrutdal","year":"2015","journal-title":"World J Nephrol"},{"key":"2025120413271332000_15.11.e107017.9","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr453"},{"key":"2025120413271332000_15.11.e107017.10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013101062"},{"key":"2025120413271332000_15.11.e107017.11","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05880420"},{"key":"2025120413271332000_15.11.e107017.12","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1681\/ASN.V1271549","article-title":"The microinflammatory state in uremia: causes and potential consequences","volume":"12","author":"Kaysen","year":"2001","journal-title":"J Am Soc Nephrol JASN"},{"key":"2025120413271332000_15.11.e107017.13","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08151109"},{"key":"2025120413271332000_15.11.e107017.14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.5301\/IJAO.2011.7748","article-title":"Combination of maintenance hemodialysis with hemoperfusion: a safe and effective model of artificial kidney","volume":"34","author":"Chen","year":"2011","journal-title":"Int J Artif Organs"},{"key":"2025120413271332000_15.11.e107017.15","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000006160","article-title":"Curative effect of neutral macroporous resin hemoperfusion on treating hemodialysis patients with refractory uremic pruritus","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"2025120413271332000_15.11.e107017.16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000376604","article-title":"Effect of the Combination of Hemodialysis and Hemoperfusion on Clearing Advanced Glycation End Products: A Prospective, Randomized, Two-Stage Crossover Trial in Patients Under Maintenance Hemodialysis","volume":"40","author":"Zhang","year":"2015","journal-title":"Blood Purif"},{"key":"2025120413271332000_15.11.e107017.17","first-page":"8563","article-title":"Comparison of combined blood purification techniques in treatment of dialysis patients with uraemic pruritus","volume":"9","author":"Zhang","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"2025120413271332000_15.11.e107017.18","unstructured":"Raine A , Cordonnier D , Ritz E . Effect of Hematodialysis plus Hemoperfusion on Insulin Resistance and Nutritional Status of Patients with End-Stage Diabetic Nephropathy. 2015."},{"key":"2025120413271332000_15.11.e107017.19","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1177\/0391398819837546","article-title":"Additional hemoperfusion is associated with improved overall survival and self-reported sleep disturbance in patients on hemodialysis","volume":"42","author":"Gu","year":"2019","journal-title":"Int J Artif Organs"},{"key":"2025120413271332000_15.11.e107017.20","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000514187","article-title":"Survival Outcomes of Hemoperfusion and Hemodialysis versus Hemodialysis in Patients with End-Stage Renal Disease: A Systematic Review and Meta-Analysis","volume":"51","author":"Cheng","year":"2022","journal-title":"Blood Purif"},{"key":"2025120413271332000_15.11.e107017.21","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1159\/000518857","article-title":"The Effect of Combination Use of Hemodialysis and Hemoperfusion on Microinflammation in Elderly Patients with Maintenance Hemodialysis","volume":"51","author":"Li","year":"2022","journal-title":"Blood Purif"},{"key":"2025120413271332000_15.11.e107017.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000525225","article-title":"Randomized Control Study on Hemoperfusion Combined with Hemodialysis versus Standard Hemodialysis: Effects on Middle-Molecular-Weight Toxins and Uremic Pruritus","volume":"51","author":"Zhao","year":"2022","journal-title":"Blood Purif"},{"key":"2025120413271332000_15.11.e107017.23","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/aor.14954","article-title":"Efficacy of HA130 Hemoadsorption in Removing Advanced Glycation End Products in Maintenance Hemodialysis Patients","volume":"49","author":"Ram\u00edrez-Guerrero","year":"2025","journal-title":"Artif Organs"},{"key":"2025120413271332000_15.11.e107017.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022169","article-title":"Randomised, open-label, multicentre trial comparing haemodialysis plus haemoperfusion versus haemodialysis alone in adult patients with end-stage renal disease (HD\/HP vs HD): study protocol","volume":"8","author":"Lu","year":"2018","journal-title":"BMJ Open"},{"key":"2025120413271332000_15.11.e107017.25","unstructured":"Zhao XY , Wang D , Liu CP , et al . Cost-effectiveness Analysis of HA Resin Hemoperfusion combined with Hemodialysis in the Treatment of End-stage Renal Disease. Health Economics Res 2023. doi:10.14055\/j.cnki.33-1056\/f.2023.08.022"},{"key":"2025120413271332000_15.11.e107017.26","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.21037\/atm-21-1100","article-title":"Cost-effectiveness analysis of hemodialysis plus hemoperfusion versus hemodialysis alone in adult patients with end-stage renal disease in China","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med"},{"key":"2025120413271332000_15.11.e107017.27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000525952","article-title":"Hemoperfusion in Maintenance Hemodialysis Patients","volume":"51","author":"Lu","year":"2022","journal-title":"Blood Purif"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-107017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:28:58Z","timestamp":1764883738000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-107017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,12]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-107017"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-107017","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}